A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease

Neurology. 2004 Oct 12;63(7 Suppl 2):S32-5. doi: 10.1212/wnl.63.7_suppl_2.s32.
No abstract available

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology
  • Antiparkinson Agents / therapeutic use*
  • Basal Ganglia / enzymology
  • Cheese / adverse effects
  • Child
  • Child, Preschool
  • Dopamine / metabolism
  • Drug Design
  • Humans
  • Hypertension / chemically induced
  • Infant
  • Middle Aged
  • Monoamine Oxidase / physiology
  • Monoamine Oxidase Inhibitors / adverse effects
  • Monoamine Oxidase Inhibitors / pharmacology
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / physiology
  • Neurotransmitter Agents / metabolism
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / enzymology
  • Selegiline / pharmacology
  • Selegiline / therapeutic use
  • Tyramine / adverse effects

Substances

  • Antiparkinson Agents
  • Monoamine Oxidase Inhibitors
  • Nerve Tissue Proteins
  • Neurotransmitter Agents
  • Selegiline
  • Monoamine Oxidase
  • Dopamine
  • Tyramine